# Exploration of the Binding Mechanism of Cyclic Dinucleotide Analogs to Stimulating Factor Proteins and the Implications for Subsequent Analog Drug Design

## TL;DR

This paper explores how cyclic dinucleotide analogs bind to proteins involved in immune responses, aiming to improve drug design for immunotherapy.

## Contribution

The study provides new insights into the binding mechanisms of CDN analogs with STING proteins through simulations and experiments.

## Key findings

- Computer simulations reveal specific interactions between CDN analogs and STING proteins.
- Findings suggest ways to optimize CDN analogs for better immunotherapy applications.
- The study combines computational and experimental approaches to guide future drug synthesis.

## Abstract

Cyclic dinucleotides (CDNs) are cyclic molecules consisting of two nucleoside monophosphates linked by two phosphodiester bonds, which act as a second messenger and bind to the interferon gene stimulating factor (STING) to activate the downstream signaling pathway and ultimately induce interferon secretion, initiating an anti-infective immune response. Cyclic dinucleotides and their analogs are lead compounds in the immunotherapy of infectious diseases and tumors, as well as immune adjuvants with promising applications. Many agonists of pathogen recognition receptors have been developed as effective adjuvants to optimize vaccine immunogenicity and efficacy. In this work, the binding mechanism of human-derived interferon gene-stimulating protein and its isoforms with cyclic dinucleotides and their analogs was theoretically investigated using computer simulations and combined with experimental results in the hope of providing guidance for the subsequent synthesis of cyclic dinucleotide analogs.